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Abstract
Live animal imaging is becoming an increasingly common technique for accurate and quantitative assessment of
tumor burden over time. Bioluminescence imaging systems rely on a bioluminescent signal from tumor cells, typi-
cally generated from expression of the firefly luciferase gene. However, previous reports have suggested that either
a high level of luciferase or the resultant light reaction produced upon addition of D-luciferin substrate can have a
negative influence on tumor cell growth. To address this issue, we designed an expression vector that allows
simultaneous fluorescence and luminescence imaging. Using fluorescence activated cell sorting (FACS), we gener-
ated clonal cell populations from a human breast cancer (MCF-7) and a mouse melanoma (B16-F10) cell line that
stably expressed different levels of luciferase. We then compared the growth capabilities of these clones in vitro by
MTT proliferation assay and in vivo by bioluminescence imaging of tumor growth in live mice. Surprisingly, we
found that neither the amount of luciferase nor biophotonic activity was sufficient to inhibit tumor cell growth,
in vitro or in vivo. These results suggest that luciferase toxicity is not a necessary consideration when designing bio-
luminescence experiments, and therefore our approach can be used to rapidly generate high levels of luciferase
expression for sensitive imaging experiments.
Findings
Bioluminescence imaging (BLI) is an increasingly popu-
lar technique for quantitatively assessing tumor growth
and the effects of therapy over time [1]. The sensitivity
and accuracy of in vivo BLI systems offers several
advantages over traditional methods of measuring sub-
cutaneous tumors using calipers [2-9]. Typically cancer
cells are engineered to express the firefly luciferase gene
and are engrafted into mice to form tumors [10]. Fol-
lowing an intraperitoneal injection of D-luciferin, the
luciferase enzyme will catalyze this substrate into oxylu-
ciferin, requiring the presence of oxygen, and cofactors
such as adenosine triphosphate (ATP) and Mg
2+ ions
[11]. The resulting light photons generated by this reac-
tion are captured non-invasively with a charge-coupled
device (CCD) camera mounted within the BLI system
[12]. Successful BLI requires prior modification of the
cancer cell line with the luciferase gene, however little is
known about the effect this may have on normal
cell function [13]. To date, the only evidence of a
detrimental effect of biophotonic emissions on cell func-
tion was in a luciferase-expressing ovarian cancer cell
line that showed a high level of luciferase reduced
tumor growth in vivo [14]. It was suggested that build
up of oxyluciferin during repeated BLI might cause oxi-
dative damage to the cells. Limiting cofactors in the
luciferase-luciferin reaction include oxygen and ATP
[15]; therefore high levels of biophotonic activity may
place extra demand for energy on the cells, possibly
leading to growth inhibition. One report even suggests
the use of luciferase in photodynamic therapy following
a 90% reduction in the survival of NIH3T3 mouse fibro-
blasts, which were stably expressing luciferase and incu-
bated with a photosensitizer [16]. However, doubts
remain as to whether luciferase can generate enough
photons to significantly inhibit the growth of cancer
cells.
To address the issue of potential luciferase toxicity
resulting from BLI, we designed a lentiviral vector that
enabled reliable selection of the level of luciferase
expression in cells. This lentiviral vector [17] encodes
green fluorescent protein (GFP) alone (Figure 1Ai) or
GFP linked to firefly luciferase (Figure 1Aii) by a 23
amino acid picornaviral 2A-like sequence from the
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sette permits equimolar expression of GFP and luciferase
via a ribosomal skipping mechanism. Human MCF-7
breast cancer or mouse B16-F10 melanoma cell lines were
stably transduced and then purified by FACS into different
fractions based on increasing levels of GFP expression.
Cell fractions were then subjected to BLI to demonstrate
that the level of GFP directly correlated to the level of luci-
ferase expression in MCF-7 cells (r
2 = 0.9819; Figure 1B)
and B16-F10 cells (r
2 =0 . 9 8 1 8 ;F i g u r e1 C ) .M C F - 7c e l l s
were substantially brighter than B16-F10 cells, both in
luminescence and GFP expression (Figure 1B, C). This
may result from differences in transduction efficiencies,
promoter efficiency, or the known absorbance of photons
by melanin in the B16-F10 cells [19].
Clonal populations of MCF-7 and B16-F10 cells
expressing a homogenous level of luciferase, were gener-
ated by expansion of individual FACS-purified cells. Sev-
eral different clones were isolated from each cell type to
represent different levels of luciferase expression. Fol-
lowing expansion, each clone was analyzed by flow cyto-
metry to ensure GFP expression remained stable after
several weeks in culture (Figure 2A). To demonstrate
the stability of the biophotonic reaction and the sensitiv-
ity of detection, B16-F10 clones were serially diluted in
culture and subjected to BLI following addition of D-
luciferin (Figure 2B). The lack of photons emitted by
untreated cells or cells transduced with GFP-containing
vector alone indicated the specificity of the biolumines-
cence reaction. To assess how luciferase biolumines-
cence in our clones compared to levels reported by
Brutkiewicz et al, we used a combination of luminome-
try and BLI (Additional File 1). The biophotonic emis-
sion of the brightest clone was 226, 818 counts per
second (CPS)/μg of protein, that represents a 1222-fold
increase in luciferase bioluminescence compared to
negative cells. We believe such levels are comparable to,
or greater, than those previously reported [14]. Hetero-
logous protein levels were also assessed by SDS-PAGE
and immunoblotting using antibodies against GFP or
the P2A sequence and indicate a range of expression
between clones (Figure 2C). The P2A epitope (~2 kDa)
remains attached to GFP post-separation, resulting in
the higher molecular weight bands observed in cells
expressing the GFP-P2A-luc cassette, compared to GFP
alone at 27 kDa. Complete separation of GFP from luci-
ferase had occurred as indicated by the absence of a
fusion protein at 90 kDa (Figure 2C).
To investigate whether biophotonic activity or the
luciferase gene itself had a negative influence on cell
growth in vitro, proliferation assays were performed.
MCF-7 (Figure 3A) or B16-F10 (Figure 3B) clones
expressing different levels of GFP-P2A-luc plus negative
controls were periodically treated with D-luciferin and
assessed for proliferation by MTT assay. All cell types
displayed similar growth dynamics, indicating neither
the presence of the luciferase gene, nor biophotonic
activity was sufficient to inhibit growth compared to
controls (Figure 3A, B). This occurred despite the high
expression of GFP-P2A-luc observed in the MCF-7 cells
by flow cytometry (Figure 3Avi). The viability of lucifer-
ase-expressing clones was also assessed using a live/dead
fluorescent stain in conjunction with flow cytometry
analysis (Additional File 2). The results revealed no sig-
nificant difference in cell viability between clones
expressing different levels of luciferase or between cells
periodically treated with D-luciferin. To determine
whether these observations extended to non-clonal
populations of cells expressing a wider range of lucifer-
ase levels, cell growth was assessed in multiple cell types
(Additional File 3). Cells transduced with GFP-P2A-luc
were purified by FACS into mixed populations expres-
sing no, low, medium or high levels of luciferase, before
being cultured with or without periodic D-luciferin
treatments. MTT assays indicated that neither the level
of luciferase, nor biophotonic activity, affected tumor
cell growth in MCF-7, B16-F10, ACHN renal and CT26
colon carcinoma cells (Additional File 3B-E respec-
tively). Furthermore, there was no difference between
FACS-purified populations of GFP- and GFP-P2A-luc-
expressing B16-F10 cells with similar GFP expression
(Additional File 3F). These observations are supported
by a previous report that found luciferase biolumines-
cence was not sufficient to generate photodynamic toxi-
city in vitro in a range of cell lines, even in the presence
of photosensitizers [20].
To validate these findings in vivo, we performed BLI
in a subcutaneous mouse tumor model. B16-F10 clonal
cells expressing GFP alone or GFP-P2A-luc (clone 4)
were injected subcutaneously into the right or left hand
flanks respectively of white C57Bl/6 mice. Animals were
divided into two cohorts; one received bi-weekly intra-
peritoneal injections of phosphate buffered saline (PBS),
and the other D-luciferin. Tumor growth was monitored
using caliper measurements (Figure 4A, B) and on the
final day tumors expressing GFP-P2A-luc from both
groups were subjected to BLI (Figure 4C, D). Following
sacrifice, tumors were extracted and weighed for com-
parison (Figure 4E). Consistent with our in vitro find-
ings, neither the presence of the luciferase gene, nor
biophotonic activity significantly inhibited tumor growth
in vivo. This finding was validated not only by caliper
measurements but also by endpoint BLI and tumor
weight data. No inhibitory effect was observed despite
the high level of GFP-P2A-luc expression of B16-F10
clone 4. Caliper and weight data did reveal an overall
size difference between tumors expressing GFP alone
and GFP-P2A-luc (Figure 4A, B and 4E). However, it is
Tiffen et al. Molecular Cancer 2010, 9:299
http://www.molecular-cancer.com/content/9/1/299
Page 2 of 8A
B
C 17 6 5 4 3 2
17 6 5 4 3 28
17 6 5 4 3 28
01 0
2
10
3
10
4
10
5
GFP
0
300
600
900
1200
C
e
l
l
n
u
m
b
e
r
Fraction number
01 0
2
10
3
10
4
10
5
GFP
0
20
40
60
80
100
C
e
l
l
n
u
m
b
e
r
17 6 5 4 3 2
Fraction number
pHIV1SDm-CMV-GFP
pHIV1SDm-CMV-GFP-P2A-luc
(i)
(ii)
GFP 5' LTR
CMV
cppt
RRE
3' LTR
Wpre
SIN
Luciferase GFP 5' LTR 3' LTR
Wpre
P2A CMV
cppt
RRE
SIN
MCF-7 cells
0 10000 20000 30000 40000
0.0 10+00
1.0 1008
2.0 1008
3.0 1008
4.0 1008
5.0 1008
r2 = 0.9819
GFP (MFI)
T
o
t
a
l
f
l
u
x
(
p
/
s
)
B16-F10 cells
0 3000 6000 9000 12000
0.0 10+00
1.0 1007
2.0 1007
3.0 1007
4.0 1007
r2 = 0.9818
GFP (MFI)
T
o
t
a
l
f
l
u
x
(
p
/
s
)
Figure 1 Lentiviral vectors designed to achieve equimolar expression of GFP and luciferase. (A) The third-generation lentiviral expression
vector pHIV1SDm [17] containing 5’ and 3’ LTRs, long terminal repeat; RRE, rev response element; cPPT, central polypurine tract; CMV,
cytomegalovirus promoter; GFP, enhanced green fluorescent protein; P2A, porcine teschovirus-1 2A motif; Wpre, woodchuck hepatitis post-
transcriptional regulatory element; and self-inactivating (SIN) 3’LTR. The vectors contained (i) GFP alone as a control, or (ii) a GFP and firefly
luciferase cassette (GFP-P2A-luc). (B) MCF-7 or (C) B16-F10 cells were transduced with a lentiviral vector containing the GFP-P2A-luc cassette and
purified into 7 or 8 different populations based on increasing GFP expression by FACS. B16-F10 (20, 000) or MCF-7 (10, 000) cells/well were
deposited in a black 96-well plate and luciferase expression was immediately confirmed upon addition of D-luciferin substrate (150 μg/mL final
concentration). Luciferase bioluminescence was quantified using the Xenogen IVIS-100 and Living Image software (Caliper Life Sciences). GFP
mean fluorescence intensity (MFI) vs. luciferase total flux (p/s = photons/second) was plotted and linear regression calculated for the line of best
fit (n = 3). All statistical analyses were performed using GraphPad Prism 5.01.
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Figure 2 Isolation of clones that stably express GFP and luciferase. B16-F10 cells were transduced with the GFP-P2A-luc lentiviral vector and
GFP- positive cells were purified by FACS (> 95%). (A) Single cell clones were isolated by limiting dilution, expanded in vitro and tested to
confirm stable expression of GFP. The specificity and sensitivity of luciferase expression was demonstrated by serial dilution of the B16-F10
clones and appropriate controls (negative = untransduced, or cells transduced with GFP only). BLI images were taken prior to or following the
addition of D-luciferin substrate (B) using a Xenogen IVIS-100. (C) Complete separation of GFP and luciferase protein was confirmed by SDS-PAGE
and immunoblotting using anti-GFP (Cat. # 632380, BD Bioscience) and anti-P2A antibodies [18]. Separated GFP protein migrated at 27 kDa,
whereas the GFP-P2A product will migrate at a higher molecular weight (~29 kDa). Un-separated GFP-P2A-luc protein was predicted to migrate
at 90 kDa and was not present. Actin was used as a loading control and detected also by immunoblotting (Cat. # A2103, Sigma).
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Figure 3 The luciferase gene or luciferase bioluminescence activity does not affect the growth of cancer cell lines in vitro. (A) MCF-7
cells were assessed for proliferation by MTT assay: i) untransduced; ii) transduced with GFP alone; iii-v) transduced with GFP-P2A-luc (clones 1-3);
vi) representative flow cytometric analysis of GFP expression in cells i-v. (B) B16-F10 cells were assessed for proliferation by MTT assay: i)
untransduced; ii) transduced with GFP alone; iii-vi) transduced with GFP-P2A-luc (clones 1-4). Cells were treated with D-luciferin substrate (150
μg/mL final concentration) diluted in media or media alone at 2-day intervals. Following 30 min incubation at 37°C in the dark, cells were
washed once with PBS and the normal growth medium was replaced. Proliferation was measured by addition of MTT substrate overnight,
followed by measuring the absorbance at 572 nm. Data is shown as the mean ± s.e.m. from 3 independent experiments.
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Page 5 of 8impossible to determine whether this difference was due
to the presence of the luciferase gene, because these
tumors arose from separate single cell clones with dif-
fering growth characteristics. Immunohistochemical ana-
lysis of Ki67 and cleaved caspase 3 using paraffin-
embedded sections from these tumors revealed no
significant difference in proliferation or apoptosis
respectively (Additional File 4). This occurred regardless
of luciferase gene expression or D-luciferin treatment.
Taken together, these data suggest that the differences
between the GFP- and GFP-P2A-luc-expressing clones
are most likely due to interclonal variation rather than a
direct affect of the luciferase gene.
Future work is needed to investigate the possibility of
an immune response against tumor cells expressing fire-
fly luciferase or P2A; however as most researchers
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Figure 4 The luciferase gene or luciferase bioluminescence does not affect the growth of tumors in mice. B16-F10 cells (1 × 10
6)
expressing GFP alone or GFP-P2A-luc (clone 4) were injected subcutaneously into the right or left flank respectively of white C57Bl/6 mice. Mice
received bi-weekly injections of either PBS or D-luciferin (150 mg/kg) and tumor growth was recorded using calipers for GFP alone (A) or GFP-
P2A-luc (B). Ellipsoid volume was determined using the formula π/6 × (L × W)
3/2 [21]. After 21 days, bioluminescent imaging was performed on
tumors expressing GFP-P2A-luc (C) using the Xenogen IVIS-100. (D) Images were analyzed using Living Image software and represented as total
flux measurements in photons/second. (E) Weight data was recorded from the excised tumors at sacrifice day 21. Statistical significance was
assessed using non-parametric (Mann-Whitney) analysis using GraphPad Prism 5.01. Data is the mean ± s.e.m. from 4 independent experiments.
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Page 6 of 8perform xenograft experiments in immune-compromised
animals, the immunogenicity of luciferase is unlikely to
be a significant concern. The use of clonal cell popula-
tions is useful to ensure a homogenous expression of
luciferase, but problems may arise due to interclonal var-
iation (Figure 4A, B). Based on the stoichiometric expres-
sion of GFP and luciferase protein, our approach also
allows selection of a polyclonal population of cells using
a narrow band of GFP expression (Figure 1B, C), thus
minimizing any interclonal variation. It has been sug-
gested that a hypoxic tumor environment can lead to a
reduction in intracellular ATP levels, that in turn may
result in an underestimation of BLI [15]. Our vector pro-
vides a solution to this problem in that imaging can be
performed using luminescence or fluorescence, to ensure
comparable measurements.
Our vector represents a versatile tool for BLI in that
fluorescence from GFP-positiv ec e l l sc o r r e l a t e sd i r e c t l y
with luciferase expression levels. Contrary to previous
reports however [14,16], we found that neither a high
level of luciferase expression, nor biophotonic activity
had a detrimental effect on cancer cell growth in vitro
or in vivo. In light of these data, we conclude that oxy-
luciferin toxicity is not an important consideration when
designing BLI experiments.
Additional material
Additional file 1: Quantifying luciferase bioluminescence. B16-F10
and MCF-7 cells were transduced with the GFP-P2A-luc-containing
lentiviral vector and GFP-positive cells were purified by FACS (> 95%).
Single cell clones were isolated by limiting dilution, and expanded in
vitro. B16-F10 and MCF-7 (2 × 10
6) clonal cells were lyzed using 5X
reporter lysis buffer from the Luciferase Assay System (Promega). The
protein concentration was then determined using a protein assay (Micro
BCA, Thermo Scientific). Cell lysate (5 μL) was mixed with 100 μLo f
Luciferase Assay Reagent in each well of a white 96-well plate using the
microinjector on the Victor2 Wallac plate reader (Perkin Elmer). (A)
Luminometry was used to measure light emissions in counts per second
(CPS) over a 5 second period. Data is quantified in CPS/μg of total
protein for each clone and represents 3 individual experiments
performed in triplicate. (B) Luciferase bioluminescence was imaged using
a Xenogen IVIS-100 by serial dilution of clones and appropriate controls
(negative = untransduced, or cells transduced with GFP only).
Bioluminescent images were taken following the addition of D-luciferin
substrate. (C) Wells containing 1 × 10
6 cells were quantified using Living
Image software and represented as total flux measurements in photons/
second.
Additional file 2: Luciferase bioluminescence does not affect tumor
cell viability in vitro. B16-F10 and MCF-7 clonal cells that stably express
luciferase were seeded in 12-well plates (2 × 10
3/well). Cells were treated
with D-luciferin substrate diluted in media or media alone at 2-day
intervals. Following 30 min incubation at 37°C in the dark, cells were
washed once with PBS and the normal growth medium was replaced.
Cell viability was measured after 8-10 days in culture using the LIVE/
DEAD Fixable Dead Cell Stain Kit (Invitrogen). The violet fluorescent dye
(1:500) was used to distinguish between live and dead cell populations
using the BD FACSCanto flow cytometer and analyzed using Flowjo
version 8.1 (Treestar). The live cell populations are represented for (A)
B16-F10 cells and (B) MCF-7 cells.
Additional file 3: A range of luciferase bioluminescence does not
affect tumor cell viability in multiple cell types. (A) Cells were
transduced with a lentiviral vector containing the GFP-P2A-luc cassette
and purified into negative, low, medium or high GFP-expressing
populations by FACS. Cells (400/well) were deposited directly into 96-
well plates and were treated with D-luciferin substrate diluted in media
or media alone at 2-day intervals. Following 30 min incubation at 37°C in
the dark, cells were washed once with PBS and the normal growth
medium was replaced. Cell viability was measured after 8-10 days in
culture by addition of MTT substrate overnight, followed by measuring
the absorbance at 572 nm for (B) MCF-7, (C) B16-F10 (D) ACHN and (E)
CT26 cells. A mixed population of B16-F10 cells were transduced with
lentivirus containing the GFP-P2A-luc cassette or GFP alone. (F) Identical
populations of GFP expressing cells were purified by FACS and cell
viability was assessed by addition of MTT substrate overnight, followed
by measuring the absorbance at 572 nm. Data is shown as the mean ±
s.e.m. from 3 independent experiments.
Additional file 4: Luciferase bioluminescence does not affect tumor
cell proliferation or viability in vivo. B16-F10 tumors expressing GFP-
P2A-luc or GFP alone were excised from animals and fixed in 10%
neutral buffered formalin. Tumors were embedded in paraffin, cut into
serial sections and mounted on lysine-coated slides. Tumor sections were
stained using a Bond Max autostainer (Leica Microsystems) with an anti-
Ki67 (Cat. # ORG-8772, Novocastra) or an anti-cleaved (c) caspase-3
monoclonal antibody (Cat. # 9664). A secondary antibody conjugated to
alkaline phosphatase followed by chromogen staining (Fast Red) was
used to distinguish between melanin and positive staining in
melanocytes. Sections were counterstained with haematoxylin. (A) Ki67
staining was assessed in: i) normal tonsil tissue (positive control); ii) GFP
alone tumors treated with PBS; iii) GFP alone tumors treated with D-
luciferin; iv) GFP-P2A-luc tumors treated with PBS; and v) GFP-P2A-luc
tumors treated with D-luciferin. Nuclear staining is indicated by arrows.
(B) c-caspase-3 staining was assessed in: i) Etoposide treated Jurkat cells
(positive control); ii) GFP alone tumors treated with PBS; iii) GFP alone
tumors treated with D-luciferin; iv) GFP-P2A-luc tumors treated with PBS;
and v) GFP-P2A-luc tumors treated with D-luciferin. Cytoplasmic staining
is indicated by arrows. Slides were then scanned and whole sections
were assessed for positive staining using the ACIS III system and software
(Dako). Statistical significance was assessed using non-parametric (Mann-
Whitney) analysis using GraphPad Prism 5.01. Data is shown as the mean
± s.e.m. from 3 tumor sections derived from one experiment.
List of abbreviations
FACS: Fluorescence activated cell sorting. MTT: 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide. BLI: Bioluminescence imaging. P2A: Porcine
teschovirus-1 2A sequence. SDS-PAGE: Sodium dodecyl sulfate
polyacrylamide gel electrophoresis. PCR: Polymerase chain reaction.
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